Top 10 GLP-1 Weight Loss Medications Transforming Health in 2026

Among completers, 91.9% lost at least 5% of body weight versus 31.5% with placebo, with one-third losing 25% or more. An NDA was submitted to the FDA on December 18, 2025, positioning it as the most advanced next-generation obesity therapy. Approval is expected by late 2026 or early 2027; no list price or commercial brand is yet available.

The oral Wegovy pill (oral semaglutide 25 mg) is the first FDA-approved oral GLP-1 specifically for weight management, eliminating the need for self-injection while matching injectable Wegovy's efficacy. Approved on December 22, 2025, and launched in January 2026, the OASIS 4 Phase 3 trial showed adherent participants lost an average of 16.6% body weight, with one-third achieving at least 20% weight loss compared to under 3% for placebo. Its cardiovascular risk-reduction indication adds clinical depth. However, the strict fasting requirement—no food for 6 hours, only 4 oz of water, and a 30-minute post-ingestion wait—creates adherence challenges. This dosing protocol is stricter than Foundayo (orforglipron), which can be taken at any time without food restrictions. At a list price of $499 per month with savings programs, it is a potent but logistically demanding option.

Foundayo (orforglipron) by Eli Lilly is the first FDA-approved non-peptide small-molecule oral GLP-1, approved on April 1, 2026, offering flexible intake with or without food—a critical real-world advantage over oral semaglutide (Wegovy oral), which requires strict fasting. The Phase 3 ATTAIN trial demonstrated a 12.4% average weight loss at 36 mg daily over 72 weeks, with 60% of participants achieving at least 10% reduction. While 12.4% is lower than oral semaglutide's 16.6%, the no-food-restriction dosing likely improves long-term adherence. A standout feature is pricing: $149 per month for self-pay patients, which is dramatically lower than every other GLP-1, with commercially insured patients paying as low as $25 via savings card. Cardiovascular outcomes trials are ongoing, and this affordability could expand GLP-1 access widely.

Ozempic (semaglutide up to 2 mg weekly) holds the most expansive FDA indications of any GLP-1, including glycemic control in type 2 diabetes, reduction of major adverse cardiovascular events, and, as of January 28, 2025, reduction of worsening kidney disease and cardiovascular death in type 2 diabetes patients with CKD. The Phase 3b FLOW trial demonstrated a 24% relative risk reduction in a composite of kidney disease worsening, end-stage kidney disease, and cardiovascular death, plus a 29% relative risk reduction in CV death—making it the only GLP-1 RA with a kidney protection indication. While not formally approved for weight management, it induces 5-10% weight reduction at 1-2 mg doses. At a monthly list price of $900-$1,000 without insurance, it provides a lower-cost entry into the GLP-1 class for millions compared to Wegovy, with better diabetes coverage.

MariTide (maridebart cafraglutide) by Amgen is a novel investigational antibody-peptide conjugate that uniquely agonizes GLP-1 while antagonizing GIP—the inverse mechanism of tirzepatide, offering a distinct metabolic pathway. Phase 2 data in the New England Journal of Medicine showed approximately 20% weight loss in non-diabetic adults after 52 weeks and about 17% in those with type 2 diabetes, with HbA1c reductions of up to 1.6 percentage points. Crucially, MariTide demonstrated sustained weight loss for up to 52 weeks after treatment stopped, a durability advantage over peptide-based GLP-1s like Ozempic (semaglutide injection), whose effects wane quickly. Its most disruptive feature is once-monthly dosing, potentially once-quarterly, versus weekly injections for all current GLP-1s. However, Phase 2 results fell short of analyst expectations, and Phase 3 trials are ongoing through 2026-2027.

Rybelsus (Oral Semaglutide 14 mg) stands alone as the only oral GLP-1 approved for both glycemic control and cardiovascular risk reduction in type 2 diabetes, a dual indication that expands its therapeutic reach since its September 2019 debut as the first oral GLP-1. By leveraging Novo Nordisk's SNAC absorption enhancer, it overcomes gastric degradation to deliver systemic absorption, and the SOUL trial (n=9,650) confirmed a 14% relative reduction in major adverse cardiovascular events versus placebo over 4 years, earning FDA approval for cardiovascular risk reduction in October 2025. Rybelsus requires strict fasting: an empty stomach, no more than 120 mL of water, and 30 minutes without food or medications. For T2D patients with established cardiovascular disease, Rybelsus remains the definitive oral option, even as oral Wegovy (25 mg) enters the market.

Saxenda (liraglutide 3 mg) pioneered chronic weight management as the first GLP-1 approved for that indication in December 2014, achieving an average 8-10% body weight loss in the SCALE trials over 56 weeks—outperforming orlistat's 3-5% average by 167%. The SCALE Obesity and Prediabetes trial reported 5.8 kg weight loss versus 1.6 kg with placebo. Once-daily injections leverage an 18-24 hour half-life, and Saxenda uniquely holds approval for adolescents aged 12-17. The key development in 2025-2026 is FDA approval of generic liraglutide, reducing monthly costs to $230-$500 compared to Saxenda's $1,349 list price; Teva's program can drop it to $20 per prescription for commercially insured patients.